title: Sipuleucel-T for the Treatment of Patients With Metastatic Castrate-resistant Prostate Cancer: Considerations for Clinical Practice.
abstract: Sipuleucel-T treatment is associated with a significant and consistent survival benefit in patients with metastatic castrate-resistant prostate cancer. Most adverse events are infusion related, manageable, and of short duration. Early screening and diagnosis of metastatic disease is important, as the greatest survival benefit may occur in patients with a lower disease burden. The short duration of sipuleucel-T treatment facilitates the use of subsequent therapies. Sipuleucel-T is now being used in the clinic for patients with a lower disease burden. We present our own experience with the use of sipuleucel-T in the setting of a large urology practice.
authors.affiliation: Associated Medical Professionals, Syracuse, NY.
authors.forename: Christopher M
authors.initials: CM
authors.lastname: Pieczonka
authors.affiliation: Associated Medical Professionals, Syracuse, NY.
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Telonis
authors.affiliation: Associated Medical Professionals, Syracuse, NY.
authors.forename: Vladimir
authors.initials: V
authors.lastname: Mouraviev
authors.affiliation: Associated Medical Professionals, Syracuse, NY.
authors.forename: David
authors.initials: D
authors.lastname: Albala
keywords: Clinical practice; Immunotherapy; Metastatic castrate-resistant prostate cancer; Sipuleucel-T
references.citation: Nat Clin Pract Oncol. 2006 Dec;3(12):658-67
references.pmid: 17139317
references.citation: J Immunol. 1997 Oct 1;159(7):3113-7
references.pmid: 9317107
references.citation: Oncogene. 2008 Oct 6;27(45):5904-12
references.pmid: 18836471
references.citation: J Urol. 2011 Sep;186(3):877-81
references.pmid: 21788048
references.citation: N Engl J Med. 2004 Oct 7;351(15):1502-12
references.pmid: 15470213
references.citation: J Biomed Biotechnol. 2011;2011:918471
references.pmid: 22190859
references.citation: Cancer. 2009 Aug 15;115(16):3670-9
references.pmid: 19536890
references.citation: Nat Rev Immunol. 2010 Aug;10 (8):580-93
references.pmid: 20651745
references.citation: J Clin Oncol. 2000 Dec 1;18(23):3894-903
references.pmid: 11099318
references.citation: Cancer Immunol Immunother. 2013 Jan;62(1):137-47
references.pmid: 22865266
references.citation: J Clin Oncol. 2003 Apr 1;21(7):1232-7
references.pmid: 12663709
references.citation: BJU Int. 2012 Jul;110(2 Pt 2):E99-104
references.pmid: 22177289
references.citation: Oncologist. 2010;15(9):969-75
references.pmid: 20798195
references.citation: Urology. 2013 Jun;81(6):1297-302
references.pmid: 23582482
references.citation: Urology. 2013 Feb;81(2):381-3
references.pmid: 23374810
references.citation: N Engl J Med. 2013 Jan 10;368(2):138-48
references.pmid: 23228172
references.citation: Clin Cancer Res. 2010 Jan 1;16(1):203-11
references.pmid: 20008841
references.citation: N Engl J Med. 2010 Jul 29;363(5):411-22
references.pmid: 20818862
references.citation: J Clin Oncol. 2006 Jul 1;24(19):3089-94
references.pmid: 16809734